Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative therapeutics for cancer treatment. The company's integrated platform combines research, development, and manufacturing capabilities for biologics. Alphamab Oncology specializes in antibody-drug conjugates, single domain antibodies/monoclonal antibodies, and multi-functional antibodies.

The company's lead product, Envafolimab, is the world's first subcutaneously injectable PD-L1 inhibitor, which received approval from Chinese authorities in 2021 for cancer treatment. Alphamab's pipeline includes several other assets in clinical development. KN046, a PD-L1/CTLA-4 bispecific antibody, is being evaluated in multiple clinical trials for various cancer types. KN026, an anti-HER2 bispecific antibody, has entered phase I clinical trials in China. JSKN003, an anti-HER2 bispecific antibody-drug conjugate, has shown promising early clinical results in patients with HER2-expressing advanced solid tumors.

Alphamab Oncology utilizes proprietary technology platforms, including protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. The company's glycan-specific conjugation platform is used to develop antibody-drug conjugates like JSKN003. As of 2024, Alphamab has several products in advanced clinical stages, with some candidates having received Breakthrough Therapy designation from Chinese regulators.

Key customers and partnerships

Alphamab Oncology has entered into collaborations with other pharmaceutical companies to advance its pipeline. In June 2024, the company announced a research and collaboration agreement with ArriVent BioPharma to utilize Alphamab's proprietary linker-payload and glycan-conjugation platforms for developing novel antibody-drug conjugates. Under this agreement, Alphamab retained rights for Greater China while ArriVent gained rights for other global markets.

In August 2021, Alphamab partnered with JMT-Bio, a subsidiary of CSPC Pharmaceutical Group, for the development and commercialization of KN026 in mainland China for breast cancer and gastric/gastroesophageal junction cancer indications. The company has also presented clinical data at major oncology conferences, indicating engagement with the broader scientific and medical community in the field of cancer research and treatment.